KR20090119959A - 약학적 제형 - Google Patents

약학적 제형 Download PDF

Info

Publication number
KR20090119959A
KR20090119959A KR1020097007466A KR20097007466A KR20090119959A KR 20090119959 A KR20090119959 A KR 20090119959A KR 1020097007466 A KR1020097007466 A KR 1020097007466A KR 20097007466 A KR20097007466 A KR 20097007466A KR 20090119959 A KR20090119959 A KR 20090119959A
Authority
KR
South Korea
Prior art keywords
active agent
salt
formulation
fenofibric acid
modified release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020097007466A
Other languages
English (en)
Korean (ko)
Inventor
이 가오
알. 주 트주치
데니스 와이 리
니콜 뉴엔
하우일리앙 우
Original Assignee
아보트 러보러터리즈
풔니어 래버러토리 아일랜드 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아보트 러보러터리즈, 풔니어 래버러토리 아일랜드 리미티드 filed Critical 아보트 러보러터리즈
Publication of KR20090119959A publication Critical patent/KR20090119959A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020097007466A 2006-10-12 2007-10-12 약학적 제형 Withdrawn KR20090119959A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82925506P 2006-10-12 2006-10-12
US60/829,255 2006-10-12

Publications (1)

Publication Number Publication Date
KR20090119959A true KR20090119959A (ko) 2009-11-23

Family

ID=38961056

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097007466A Withdrawn KR20090119959A (ko) 2006-10-12 2007-10-12 약학적 제형

Country Status (14)

Country Link
EP (1) EP2081563A1 (enExample)
JP (1) JP2010506855A (enExample)
KR (1) KR20090119959A (enExample)
CN (1) CN101677981A (enExample)
AU (1) AU2007307641A1 (enExample)
CA (1) CA2672686A1 (enExample)
CO (1) CO6160302A2 (enExample)
EA (1) EA200900531A1 (enExample)
EC (1) ECSP099251A (enExample)
IL (1) IL198160A0 (enExample)
MX (1) MX2009003815A (enExample)
SG (1) SG175570A1 (enExample)
WO (1) WO2008046052A1 (enExample)
ZA (1) ZA200902488B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2285357T3 (da) * 2008-05-30 2014-06-02 Ucb Pharma Sa Farmaceutisk sammensætning omfattende brivaracetam
CN102304103A (zh) * 2011-06-03 2012-01-04 郑州泰基鸿诺药物科技有限公司 一种非诺贝特酸盐、制备方法、药物组合物及应用
CN102659570B (zh) * 2012-05-17 2014-05-28 安润医药科技（苏州）有限公司 二氟非诺贝特酸及其在药学上可接受的盐，以及它们的制备方法和应用
FR3050112B1 (fr) * 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
CN107496397A (zh) * 2016-06-14 2017-12-22 重庆安格龙翔医药科技有限公司 一种二甲双胍与非诺贝酸的复合物及其制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572190B1 (en) * 2002-12-17 2007-04-18 Abbott GmbH & Co. KG Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
EP1829541A1 (en) * 2002-12-17 2007-09-05 Abbott GmbH & Co. KG Formulation comprising fenofibric acid or a physiologically acceptable salt thereof
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
JP5114382B2 (ja) * 2005-04-08 2013-01-09 アボット・ラボラトリーズ フェノフィブリン酸および／またはそれの塩を含む経口医薬製剤

Also Published As

Publication number Publication date
SG175570A1 (en) 2011-11-28
WO2008046052A1 (en) 2008-04-17
CN101677981A (zh) 2010-03-24
JP2010506855A (ja) 2010-03-04
EA200900531A1 (ru) 2009-12-30
MX2009003815A (es) 2009-09-07
CA2672686A1 (en) 2008-04-17
IL198160A0 (en) 2009-12-24
AU2007307641A1 (en) 2008-04-17
ECSP099251A (es) 2009-06-30
EP2081563A1 (en) 2009-07-29
ZA200902488B (en) 2010-10-27
CO6160302A2 (es) 2010-05-20

Similar Documents

Publication Publication Date Title
JP5788331B2 (ja) 浸食マトリックス中に１またはそれ以上のフマル酸エステルを含む医薬製剤
RU2739302C2 (ru) Антисмысловые композиции и способы их получения и применения
JP2916978B2 (ja) 放出開始制御型製剤
JP5366549B2 (ja) 即時放出特性及び／又は制御放出特性を有する薬学的剤形
US20130085181A1 (en) Pharmaceutical formulations
US8709996B2 (en) Pharmaceutical treatment process using chitosan or derivative thereof
JP5517932B2 (ja) ラモトリジンの改良製剤
US11291660B2 (en) Method of treating heart failure with preserved ejection fraction by administering milrinone
KR20210147082A (ko) 디메틸푸마레이트를 포함하는 일일 저용량 투여용 약제학적 조성물
RU2610435C2 (ru) Таблетка месалазина с улучшенной растворимостью
JP2009543885A (ja) イブプロフェンの投与のための方法および医薬
JP2009517346A5 (enExample)
JP2009517346A (ja) 治療用化合物の経口送達系
KR20090119959A (ko) 약학적 제형
AU2015326392B2 (en) Pharmaceutical compositions comprising alpelisib
JP2009519313A (ja) 医薬組成物
US20100226980A1 (en) Novel tablet based on s-adenosyl-methionine
WO2018062955A1 (ko) 라코사미드 서방성 제제
Lakshmi et al. Formulation and evaluation of aceclofenac floating microspheres
NZ732954B2 (en) Method of Treating Heart Failure with Preserved Ejection Fraction with 5-(Pyridinyl)-2(1H)-pyridinone Compounds
US20140066411A1 (en) Pharmaceutical compositions for extended release of azo-bonded 5-aminosalicylic acid compositions
EA042106B1 (ru) Фармацевтический состав, содержащий один или более эфиров фумаровой кислоты в разлагаемой матрице

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090410

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid